Fig. 8: Anticancer efficacy evaluation in vivo.
a Time-dependent concentration of FHPG in blood of HeLa-tumor-bearing mice after intravenous administration. Data are expressed as mean ± SD (N = 3 biologically independent animals). The circulation half-time (T1/2) of FHPG was calculated to be 1.75 h. b Distribution of Si element in main organs (hearts, livers, spleens, lungs, and kidneys) and tumors of mice at varied time points after FHPG administration. Data are expressed as mean ± SD (N = 3 biologically independent animals). c Scheme for the schedule of in vivo FHPG treatment. d Time-dependent growth curves of HeLa tumor xenografts in mice after treatments with: (1) PBS (control), (2) Fe-HMSN-PEG, (3) gallate, or (4) FHPG. Data are expressed as mean ± SD (N = 5 biologically independent animals). **P < 0.01, based on the Student’s two-sided t-test. e Body weight changes of HeLa-tumor-bearing mice after various treatments in (d). Data are expressed as mean ± SD (N = 5 biologically independent animals). n.s., not significant, based on the Student’s two-sided t-test. f Histochemical analyses (GPX4, H&E, TUNEL) of HeLa tumor tissue harvested from mice after various treatments on day 14, representative of five biological replicates from each experimental group. Scale bar, 50 μm. Source data are provided as a Source Data file.
